Aakaar Medical TechnologiesShare price, financial results, shareholding and management

NSE Emerge · AAKAARMedical aesthetics supplyListed 27 June 2025IPO ₹72Catch them young
aakaarmedical.in ↗Live price on NSE ↗ISIN INE1GYP01013 · Lot 1,600 shares · ₹1.06 lakh
₹66.00
+0.60% on the day
Close · 17 Nov 2026
Valuation
Market cap
₹94 cr
Stock P/E
14.1peers 44.2
Book value
₹38.5
Price to book
1.71
EV / operating profit
9.3
Market cap to sales
1.40
Returns and growth
ROCE · FY26
18.5%
ROE · FY26
17.1%
ROE, 3-year average
25.6%
Operating margin · FY26
15.4%peers 14.0%
Sales growth, 3 years
26.9%
Profit growth, 3 years
45.6%
Safety
Debt to equity
0.34peers 0.14
Borrowings
₹18.5 cr
Interest cover
6.1×
Cash from business / op. profit
-81%
Debtor days
203
Pledged
0.00%
Ownership and share
Promoter holding
67.05%
Change in promoter holding
+0.04 pts
Shareholders
550
52-week high / low
₹85 / ₹46
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

Aakaar Medical Technologies share price chart

₹66.00-14.89% 1 year

Close on 17 Nov 2026 · +0.61% on the day · Vol 6,400

Daily prices to 17 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 17 Nov 2026

1 month
-7.0%
3 months
+24.4%
6 months
+9.9%
1 year
-14.9%
Since IPO
-8.3%
Traded a day, 20 days
₹0.07 cr
Taken for delivery
95%

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+9%+10%
3 years, a year+27%+46%
Latest half, H2 FY26+23%+33%

About Aakaar Medical Technologies: business, products and customers

Aakaar Medical Technologies sells skin and hair care products, injectables and aesthetic devices to dermatologists and skin clinics across India, partly under its own brands and partly as the Indian seller of foreign brands. Its shares trade on NSE Emerge.

Aakaar, based in Mumbai, sells only to doctors: dermatologists, plastic surgeons and aesthetic clinics, who use the products in treatments or pass them on to patients. It carries about 150 products from brands in Korea, Spain, Italy, Austria and the USA, such as the fillers of Croma and the botulinum toxin Letybo, alongside its own brands like the DRS1512 hair range, which contract manufacturers make to its formulas. It owns no factory.

Own brands earn a much higher gross margin than imported ones, so the mix between them moves profit. Doctors have long been sold on credit, through a consignee agent, Parekh Integrated Services, that stores the goods, bills the doctors and collects; so money owed by customers is large, and the company has started moving to local stockists who pay within weeks. Conferences and workshops are held early in the year and sales are heavier later, so the first half earns little and the second half carries the year.

Read more about the business

The offer document says no listed company in India or abroad has a comparable business. Its industry section names Allergan, Alma and Galderma among the foreign brands in Indian aesthetics, and Skinnovation, Kaya and Dr. Reddy's Laboratories among the domestic ones. In FY26 the company launched Letybo, exosome ranges from Italy and Korea and a DermLite device, and started Xelix, a network of partner clinics.

From the red herring prospectus (June 2025), the FY26 annual report, the investor presentation of June 2026 and the earnings call transcripts of November 2025 and May 2026.

Read the deeper study ↓

In its favour

  • Sales have grown fast: 27% a year over three years.
  • The promoters own a large part of the company: 67.05%.

To watch

  • The move to stockists for more than 90% of sales from April 2026 and whether debtor days fall towards the 100 to 110 management talks of.
  • Sales growth in FY27 against the 30% or more the chief executive aims for, and whether the first half improves on FY26.
  • Use of the ₹11.0 cr of working capital money and ₹3.3 cr for general purposes still unspent from the IPO at March 2026.
  • Recovery of the ₹0.40 cr deposit flagged by the auditor, and the Xelix clinic count against the 50 targeted.
  • Customers take longer to pay than before: 203 days in FY26, against 118 in FY20.

From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.

Aakaar Medical Technologies revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown fast. Last year profit grew roughly in step with sales.

Sales and net profit, every year, ₹ crore
SalesNet profit
020406080Sales, FY20: 22.9 ₹ cr22.9Net profit, FY20: 1.8 ₹ cr1.8FY20Sales, FY21: 12.4 ₹ cr12.4Net profit, FY21: 0.5 ₹ cr0.5FY21Sales, FY22: 19.5 ₹ cr19.5Net profit, FY22: 1.6 ₹ cr1.6FY22Sales, FY23: 32.8 ₹ cr32.8Net profit, FY23: 2.2 ₹ cr2.2FY23Sales, FY24: 46.1 ₹ cr46.1Net profit, FY24: 2.9 ₹ cr2.9FY24Sales, FY25: 61.6 ₹ cr61.6Net profit, FY25: 6 ₹ cr6FY25Sales, FY26: 67 ₹ cr67Net profit, FY26: 6.6 ₹ cr6.6FY26
The latest halves, ₹ crore
SalesNet profit
-200204060Sales, H2FY25: 33.9 ₹ cr33.9Net profit, H2FY25: 5.6 ₹ cr5.6H2FY25Sales, H1FY26: 25.3 ₹ cr25.3Net profit, H1FY26: -0.8 ₹ cr-0.8H1FY26Sales, H2FY26: 41.6 ₹ cr41.6Net profit, H2FY26: 7.4 ₹ cr7.4H2FY26

SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.

Aakaar Medical Technologies half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H2FY25H1FY26H2FY26
Sales33.8825.3241.64
Expenses25.5325.5631.22
Operating profit8.35-0.2310.41
OPM24.6%-0.9%25.0%
Interest0.911.040.76
Depreciation0.070.050.08
Profit before tax7.48-1.0210.22
Net profit5.57-0.787.42

Aakaar Medical Technologies profit and loss

Full years to March, FY20 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Sales22.8912.4419.4732.7846.1161.5866.96
Expenses20.0111.5417.0729.2541.1151.8156.65
Operating profit2.880.902.403.5359.7710.31
OPM12.6%7.2%12.3%10.8%10.8%15.9%15.4%
Other income0.120.120.040.090.160.180.80
Interest0.460.230.210.431.141.711.80
Depreciation0.040.030.020.090.140.120.13
Profit before tax2.500.762.213.103.888.129.19
Tax rate26.8%28.9%26.7%30.6%26.0%25.7%27.7%
Net profit1.830.541.622.152.876.036.64
EPS ₹1835423.1430.71415.794.99
Dividend payout0.0%0.0%34.6%24.4%0.0%0.0%0.0%

Aakaar Medical Technologies profitability

Margins and returns on capital

Last year the company kept about as much from each rupee of sales as the year before. It earns a moderate return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

0%5%10%15%20%FY20: 12.6%12.6%FY20FY21: 7.2%7.2%FY21FY22: 12.3%12.3%FY22FY23: 10.8%10.8%FY23FY24: 10.8%10.8%FY24FY25: 15.9%15.9%FY25FY26: 15.4%15.4%FY26
Per cent
FY20FY21FY22FY23FY24FY25FY26
Operating margin12.6%7.2%12.3%10.8%10.8%15.9%15.4%
Tax rate26.8%28.9%26.7%30.6%26.0%25.7%27.7%
ROCE·8.2%20.9%25.8%23.3%26.7%18.5%
ROE·7.6%21.0%24.3%25.9%33.7%17.1%
Dividend payout0.0%0.0%34.6%24.4%0.0%0.0%0.0%

Aakaar Medical Technologies debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown fast. Its loans are smaller than its own money. Last year the business used more cash than it brought in. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
0204060Net worth, FY20: 6.9 ₹ cr6.9Borrowings, FY20: 5.9 ₹ cr5.9FY20Net worth, FY21: 7.4 ₹ cr7.4Borrowings, FY21: 3.9 ₹ cr3.9FY21Net worth, FY22: 8 ₹ cr8Borrowings, FY22: 3.8 ₹ cr3.8FY22Net worth, FY23: 9.7 ₹ cr9.7Borrowings, FY23: 5.9 ₹ cr5.9FY23Net worth, FY24: 12.5 ₹ cr12.5Borrowings, FY24: 15.1 ₹ cr15.1FY24Net worth, FY25: 23.3 ₹ cr23.3Borrowings, FY25: 22.7 ₹ cr22.7FY25Net worth, FY26: 54.6 ₹ cr54.6Borrowings, FY26: 18.5 ₹ cr18.5FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
-10-50510Cash from the business, FY20: -0.4 ₹ cr-0.4Net profit, FY20: 1.8 ₹ cr1.8FY20Cash from the business, FY21: 4.3 ₹ cr4.3Net profit, FY21: 0.5 ₹ cr0.5FY21Cash from the business, FY22: 0.5 ₹ cr0.5Net profit, FY22: 1.6 ₹ cr1.6FY22Cash from the business, FY23: -2.9 ₹ cr-2.9Net profit, FY23: 2.2 ₹ cr2.2FY23Cash from the business, FY24: -8 ₹ cr-8Net profit, FY24: 2.9 ₹ cr2.9FY24Cash from the business, FY25: -5.4 ₹ cr-5.4Net profit, FY25: 6 ₹ cr6FY25Cash from the business, FY26: -8.4 ₹ cr-8.4Net profit, FY26: 6.6 ₹ cr6.6FY26

Bars below the line are cash going out.

Aakaar Medical Technologies balance sheet

At each 31 March · ₹ crore

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Equity capital0.100.100.700.700.7010.4214.17
Reserves6.757.307.338.9611.8412.8440.38
Net worth6.857.408.039.6612.5423.2654.55
Borrowings5.883.883.825.8715.0522.7418.53
Other liabilities3.563.036.157.706.428.166.34
Total liabilities16.2914.311823.2334.0154.1679.42
Fixed assets0.060.040.200.360.280.240.29
Capital work in progress0000000.40
Investments0.470.1100000
Other assets15.7614.1617.8022.8733.7353.9278.73
Receivables······37.23
Inventory······19.75
Cash······16.24
Trade payables······1.88

Aakaar Medical Technologies cash flow

₹ crore

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Cash from operations-0.384.310.48-2.93-8.04-5.41-8.36
Cash from investing0.100.37-0.23-0.32-0.04-0.050.05
Cash from financing0.28-2-0.811.178.1910.7118.80
Net cash flow02.68-0.56-2.080.115.2510.49
Capital spending······0.58

Working capital

Days

Days
FY20FY21FY22FY23FY24FY25FY26
Debtor days118136104114129166203
Inventory days234366282274247202256
Days payable28996562324924
Cash conversion cycle324403321326344320434
Working capital days1892381051029497199

Aakaar Medical Technologies peers and competitors

Listed SME companies in the same industry

By sales, Aakaar Medical Technologies is number 5 of the 8 listed SME companies in personal products.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Anondita Medicare1,90356.01373437.0%0.26
H. R. Hygiene Products13912.61301114.0%0.51
Recode Studios48644.2801121.0%0.30
Medistep Healthcare294.970.8611.6%0.14
Aakaar Medical Technologies9414.1676.615.4%0.34
Macobs Technologies19567.241.42.98.3%0.06
Ravelcare6813.1275.226.2%0.00
Novateor Research Laboratories23227.03.80.1-2.6%0.09
Median of the 7 others13944.270.8614.0%0.14

Aakaar Medical Technologies shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own more than half the company. Foreign and Indian funds own a noticeable share. The number of shareholders has come down.

Promoters
67.05%
+0.04 pts since Jun 25
Foreign investors (FIIs)
0.50%
at Sep 25; not in the latest pattern
Indian institutions (DIIs)
11.17%
-1.16 pts since Jun 25
HNIs (over ₹2 lakh each)
6.60%
+1.27 pts since Jun 25
Small holders (up to ₹2 lakh)
9.39%
-1.87 pts since Jun 25
Companies and others
5.79%
+3.59 pts since Jun 25
Number of shareholders
550
920 in Jun 25

Aakaar Medical Technologies shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Jun 25Sep 25Mar 26
Promoters67.01%67.01%67.05%
Foreign investors (FIIs)1.87%0.50%-
Indian institutions (DIIs)12.33%10.73%11.17%
HNIs (over ₹2 lakh each)5.33%7.31%6.60%
Small holders (up to ₹2 lakh)11.26%9.16%9.39%
Companies and others2.20%5.29%5.79%
Number of shareholders920603550

The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.

Aakaar Medical Technologies study: the business from its own documents

Read from 7 of the company's own documents

Aakaar Medical Technologies so far

From the company's own record

  1. June 2013Company formed
  2. 27 June 2025Listed on NSE Emerge at ₹72
  3. 31 March 2026Promoters at 67.05%
  4. 21 July 2025Highest close since listing, ₹87.83

Aakaar Medical Technologies key facts from the filings

Each figure with the document it comes from

Own brands
37%
Share of FY26 revenue from the company's own brands, which helped gross margin rise from 54% to 59%.Earnings call transcript, May 2026, p.4
Doctors served
6,300+
Doctors and clinics billed in FY26, up from about 5,200 a year earlier.Investor presentation, June 2026, p.7; Earnings call transcript, May 2026, p.4
Top ten customers
8.16%
Share of FY25 revenue from the ten largest buyers; no single doctor matters much.Red herring prospectus, p.146
Top ten suppliers
84.89%
Share of FY25 cost of goods from ten suppliers, the largest at 16.39%.Red herring prospectus, p.141
Sales through one agent
80.88%
Share of FY25 revenue billed through the consignee agent Parekh Integrated Services, which also collects the dues.Red herring prospectus, p.33
Show 5 more facts
First half against second
38% / 62%
Split of FY26 sales between the halves; the first half lost ₹0.78 cr and the second earned ₹7.4 cr.Earnings call transcript, May 2026, p.4 and p.5
Money owed by doctors
₹37.2 cr
Trade receivables at March 2026, up from ₹28.0 cr, on FY26 sales of ₹67.0 cr.Annual report FY26, p.50
Cash from operations
₹-8.4 cr
FY26 operating cash flow, after ₹-5.4 cr in FY25, as receivables and stock grew.Annual report FY26, p.52
IPO money unspent
₹14.3 cr
Held in a fixed deposit at March 2026, mostly the working capital share due to be used in FY27.Annual report FY26, p.60; Earnings call transcript, May 2026, p.12
Auditor's emphasis
₹0.40 cr deposit
Placed with Accredited Consultants for a bank guarantee in that firm's legal case; recovery depends on the outcome.Annual report FY26, p.41

What the company said, and what happened

The company's own statements, attributed, set against what it later reported; not newboard's estimates

At the May 2026 call the chief executive said the company aims to keep growing at 30% a year or more, expects FY27 growth to be better than FY26 and the first half to be better than last year's, and hopes to move to the main board within about three years. The company is shifting to stockists for more than 90% of sales from April 2026 with payment due in 40 to 45 days, aims to bring debtor days down to about 100 to 110, and expects at least 50 Xelix partner clinics by the end of the year, from 16.

30%+Yearly growth aimed forMay 2026 call
90%+Sales through stockistsPlanned for FY27
50Xelix partner clinicsTarget for the year, 16 signed
What management saidWhenWhat happened
Sales growth of 25% to 30% in FY26November 2025 callSales up 8.7%, to ₹67.0 cr

Is it a good business? Six questions

Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.

Aakaar earns a trading margin on foreign aesthetic brands and a richer one on its own products, sold to thousands of skin doctors.

Its weak spots are long credit to doctors, cash tied in stock and receivables, dependence on a few foreign suppliers, and a year whose profit comes almost all in the second half.

AverageCan it set its own prices?On its own brands, yes to a fair degree; on imported brands the margin is set with the foreign owner and competes with global companies.
The evidence. Management keeps a gross margin target of about 60% and says the hair range DRS1512 earns over 80%; price increases were taken only on new stock in 2026.Earnings call transcript, May 2026, p.5, p.6 and p.11
AverageHow strong is it against rivals?It has a wide range and long ties with doctors, but competes with large global and Indian companies, and its imported brands can change hands.
The evidence. The industry section names Allergan, Alma, Galderma, Kaya and Dr. Reddy's in this market; the offer document lists dependence on third party manufacturers and brand agreements as risks.Red herring prospectus, p.125 and p.31
StrongWho are its customers?Thousands of doctors and clinics, none of them large, so losing one barely matters.
The evidence. The ten largest customers gave 8.16% of FY25 revenue; more than 6,300 doctors were billed in FY26.Red herring prospectus, p.146; Earnings call transcript, May 2026, p.4
WatchDoes it need a lot of money?Not for plants, but a lot for credit to doctors and stock, and operating cash has been negative for years.
The evidence. Receivables were ₹37.2 cr and inventory ₹19.8 cr at March 2026; operating cash flow was negative ₹8.4 cr in FY26; ₹20.4 cr of the IPO was set aside for working capital.Annual report FY26, p.50, p.52 and p.60
StrongCan it keep finding new work?Yes so far. It adds doctors and new products each year and has a pipeline of approvals for imported products.
The evidence. Five launches in FY26 including Letybo and two exosome ranges; doctors billed rose by about a fifth in the year.Earnings call transcript, May 2026, p.3 and p.4
WatchDo good and bad years swing a lot?Within each year, yes: the first half carries the event costs and the second half most of the sales and profit. Across years it has stayed profitable, but growth slowed sharply in FY26.
The evidence. FY26 first half loss of ₹0.78 cr against second half profit of ₹7.4 cr; management says profit has been positive for ten years.Earnings call transcript, May 2026, p.3 and p.4

Who runs Aakaar Medical Technologies?

Promoters, directors and officers; tap a name for the background

DRDilip Ramesh MeswaniPromoter and Managing Director · holds 48.20%

Bachelor of Science from the University of Bombay and a post diploma in Medical Electronics from Shri Bhagubhai Mafatlal Polytechnic, with over 24 years in medical aesthetics; began in aesthetics in 1999 through a proprietary business selling aesthetic devices, sole proprietor of Coherent Medical Systems since 1998, and a director since the company was formed in 2013. Managing Director for five years from July 2024.

Red herring prospectus, p.129, p.171 and p.173
BDBindi Dilip MeswaniPromoter, Chairperson and Non-Executive Director · holds 12.84%

Master of Commerce from Maharaja Sayajirao University of Baroda, with over 10 years in medical aesthetics; a director since 2013 and also a director of Revigen Medicare. The offer document states that Dilip Ramesh Meswani and Bindi Dilip Meswani are husband and wife.

Red herring prospectus, p.173 and p.174
RBRahul Babasaheb SawakhandeChief Executive Officer and Executive Director · holds 4.10%

Bachelor of Medicine and Surgery from Maharashtra University of Health Sciences, Nashik, and a diploma in business management; over 15 years in dermatology and medical regulatory affairs at Piramal Healthcare, Abbott Healthcare, Pfizer and Galderma India before joining as head of business in December 2015.

Red herring prospectus, p.173
RPRakesh Pramod ParekhChief Financial Officer

Appointed Chief Financial Officer from 12 December 2025, after Sweta Shah resigned from the post.

Annual report FY26, p.22
DPDeepanjan PeriwalIndependent Director

Chartered Accountant and Bachelor of Commerce from Nagpur University, with a senior management programme from IIM Ahmedabad and registration as a valuer; earlier with Ernst & Young and now with City First Financial Advisors; over 15 years in accounts and finance. On the board since December 2024.

Red herring prospectus, p.173
RIRajendra Indubhai DhandhukiaIndependent Director

Bachelor of Science from the University of Bombay and a diploma in marketing and sales management from Bhartiya Vidya Bhavan, with over 15 years in the pharmaceutical industry, earlier at Abbott India. On the board since December 2024.

Red herring prospectus, p.174

Aakaar Medical Technologies latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • H2 FY26: sales ₹41.6 cr (+23%), net profit ₹7.4 cr (+33%) on H2 FY25.
  • Shareholding, 31 March 2026: promoters 67.01% to 67.05%; Aarth AIF Growth Fund up to 3.61%.

Aakaar Medical Technologies annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Offer document
Earnings calls
Annual reports

Aakaar Medical Technologies share split, bonus and dividends

From the corporate actions the company announces on the exchange

No share split, bonus issue or dividend is on record since listing.

Checks we ran on Aakaar Medical Technologies' data · 9

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (1,41,72,816 shares).
  • ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
  • ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • ✓The two half-years of FY26 add up to the full-year sales.
  • !Earnings per share changes basis between FY21 (₹54.00) and FY22 (₹23.14) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
  • ✓Revenue and profit are reported for every year shown, FY20 to FY26.
  • iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.

Questions people ask about Aakaar Medical Technologies

What does Aakaar Medical Technologies do?

Aakaar Medical Technologies sells skin and hair care products, injectables and aesthetic devices to dermatologists and skin clinics across India, partly under its own brands and partly as the Indian seller of foreign brands. Its shares trade on NSE Emerge.

What is the share price of Aakaar Medical Technologies?

₹66 at the close on 17 Nov 2026, from the exchange's daily figures.

What is the market cap of Aakaar Medical Technologies?

₹94 cr at the close on 17 Nov 2026, on 1,41,72,816 shares.

What is the P/E of Aakaar Medical Technologies?

14.1 times FY26 profit at the close on 17 Nov 2026 (our arithmetic).

What are Aakaar Medical Technologies' revenue and profit?

Revenue ₹67 cr and profit after tax ₹7 cr in FY26.

Who are the promoters of Aakaar Medical Technologies?

Dilip Ramesh Meswani, Bindi Dilip Meswani; promoters held 67.05% at 31 March 2026.

What was the IPO price of Aakaar Medical Technologies?

₹72 a share; it listed on 27 June 2025.

What is Aakaar Medical Technologies' website?

aakaarmedical.in

More SME companies like Aakaar Medical Technologies

Other listed SME companies in personal products, the closest in size first, each read from its own documents.

Every listed SME company in Personal Products → · SME companies listed in 2025 →

Built from 2 earnings call transcripts, 2 investor presentations, 2 annual reports, 1 offer document, 27 exchange announcements, 3 shareholding patterns and 7 years of reported results. Every figure carries its source; where the documents are silent, the page says so.